Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
MicroRNA 4691 (MIR4691) is a human microRNA; a single-stranded, non-protein coding RNA of approximately 19–25 nucleotides in length. MicroRNAs bind to complementary sequences in the 3′ untranslated regions (UTRs) of target mRNAs and repress their translation or cause degradation. Specifically, miR-4691-3p has been shown to participate in the regulation of inflammation in human dental pulp by directly targeting the STING protein, thereby inhibiting the cGAS-STING innate immune pathway and downstream cytokine production such as IFN-β, TNF, and IL-6. There are no known transcripts produced from the MIR4691 gene itself, consistent with typical microRNA gene function, and its roles are achieved through post-transcriptional gene silencing. In research settings, synthetic inhibitors and agomirs are available to suppress or mimic miR-4691-3p, facilitating functional studies of its biological impact. There are currently no approved drugs directly targeting MIR4691 in clinical practice.
Antisense inhibition of the mature miRNA (for the inhibitor); Mimicry or overexpression of the miRNA function (for the agomir/miRNA mimics)
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on microRNA 4691 (MIR4691).